Trypanosomiasis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Trypanosomiasis – Drugs In Development, 2023’, provides an overview of the Trypanosomiasis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trypanosomiasis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Trypanosomiasis
- The report reviews pipeline therapeutics for Trypanosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Trypanosomiasis therapeutics and enlists all their major and minor projects
- The report assesses Trypanosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Trypanosomiasis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Trypanosomiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Trypanosomiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
7 Hills Pharma LLCAN2 Therapeutics Inc
Appili Therapeutics Inc
AstraZeneca Plc
Bacoba AG
Biokawthar Technologies SAS
BioLingus AG
Central Drug Research Institute
Cesa Alliance SA
Collaborations Pharmaceuticals Inc
ConserV Bioscience Ltd
Daiichi Sankyo Co Ltd
DetectoGen Inc
Diakonos Research Ltd
Drugs for Neglected Diseases initiative
Dultech Advanced Sciences
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Flanders Institute for Biotechnology
Foundation For Neglected Disease Research
Fox Chase Chemical Diversity Center Inc
Ghent University
GSK plc
Helmholtz Center Munich German Research Center for Health and Environment GmbH
Helmholtz Centre for Infection Research
Hospital Universitrio Professor Edgard Santos
iBio Inc
Immune Modulation Inc
Impetis Biosciences Ltd
Institut Pasteur Korea
Isfahan University of Medical Sciences
Kitasato University
Macrophage Therapeutics Inc
ManRos Therapeutics
Massachusetts College of Pharmacy and Health Sciences
McGill University Health Center
MedC Biopharma Ltd
MediSynergics LLC
Molecular Targeting Technologies Inc
Mycosynthetix Inc
Nanomerics Ltd
NorthShore University Health System
Novartis AG
NYU Langone Health System
Oblita Therapeutics BVBA
Ohio State University
Pai Life Sciences Inc
Pasteur Institute
Paxmedica Inc
Pfizer Inc
Pharos iBio Co Ltd
Rakta Therapeutics Inc
RIKEN
Sanofi
Satellos Bioscience Inc
SATT AxLR SAS
Scynexis Inc
Selva Therapeutics Inc
Spanish National Research Council
St. John's University
Synstar Japan Co Ltd
The Lundquist Institute
Trinity College Dublin
University of Bologna
University of California San Francisco
University of Dundee
University of Edinburgh
University of Georgia
University of Glasgow
University of Nantes
University of Strathclyde
University of Texas at El Paso
University of Valencia
University of Washington
University of York
Vanderbilt University
Walter Reed Army Institute of Research